Clinical Trial Update: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type [Phase 4]

View source ↗

Summary

Phase 4 trial update reports completion of a study evaluating celiprolol in patients with vascular Ehlers-Danlos syndrome and related 2q31.2 deletion syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromosome 2q31 2 Deletion Syndrome
• Ehlers-danlos Syndrome Vascular Type

Drugs mentioned

• Celiprolol (celiprolol)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME | Phase 4 | Status: COMPLETED